BlackRock
LXEO icon

BlackRock’s Lexeo Therapeutics LXEO Stock Holding History

BlackRock’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.3M Buy
5,110,871
+203,308
+4% +$1.44M ﹤0.01% 2840
2025
Q4 		$48.7M Buy
4,907,563
+2,736,471
+126% +$25M ﹤0.01% 2532
2025
Q3 		$14.4M Buy
2,171,092
+343,128
+19% +$1.66M ﹤0.01% 3269
2025
Q2 		$7.35M Sell
1,827,964
-14,268
-0.8% -$46.9K ﹤0.01% 3569
2025
Q1 		$6.39M Buy
1,842,232
+20,266
+1% +$89.8K ﹤0.01% 3534
2024
Q4 		$12M Buy
1,821,966
+191,679
+12% +$1.51M ﹤0.01% 3334
2024
Q3 		$14.7M Buy
1,630,287
+838,703
+106% +$10M ﹤0.01% 3214
2024
Q2 		$12.7M Buy
791,584
+128,622
+19% +$1.87M ﹤0.01% 3243
2024
Q1 		$10.4M Buy
662,962
+493,066
+290% +$7.71M ﹤0.01% 3334
2023
Q4 		$2.28M Buy
+169,896
New +$2.11M ﹤0.01% 3995

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock's LXEO Position: Q1 2026 in Review

BlackRock increased its Lexeo Therapeutics (LXEO) stake by 4.1% in Q1 2026, buying an estimated $1.44M and bringing the position to 5,110,871 shares worth $29.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2840.

BlackRock first reported a position in LXEO in Q4 2023 and has held it in 10 quarters since. The position peaked at $48.7M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • BlackRock held 5,110,871 shares of Lexeo Therapeutics worth $29.3M as of Q1 2026.
  • BlackRock bought 203,308 Lexeo Therapeutics shares in Q1 2026, an estimated $1.44M.
  • Lexeo Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2840 holding.
  • BlackRock first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • BlackRock's Lexeo Therapeutics position peaked at $48.7M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.